220 patents
Page 3 of 11
Utility
Compounds and Methods for Modulating C90RF72
19 Jan 23
Disclosed herein are compounds and methods for modulating C9orf72 transcript.
Thazha P. PRAKASH, Frank RIGO, David COREY
Filed: 4 Feb 22
Utility
Selective Antisense Compounds and Uses Thereof
5 Jan 23
The present invention provides oligomeric compounds.
Michael Oestergaard, Punit P. Seth, Eric E. Swayze
Filed: 27 Jan 22
Utility
Compounds and Methods for Modulating Factor XII
5 Jan 23
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of FXII RNA in a cell or subject, and in certain instances reducing the amount of FXII protein in a cell or subject.
Susan M. Freier, Huynh-Hoa Bui, Chenguang Zhao, Brett P. Monia, Jeffrey R. Crosby
Filed: 17 Dec 21
Utility
Compounds and Methods for Modulating UBE3A-ATS
29 Dec 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of UBE3A-ATS, the endogenous antisense transcript of ubiquitin protein ligase E3A (UBE3A) in a cell or subject, and in certain instances increasing the expression of paternal UBE3A and the amount of UBE3A protein in a cell or subject.
Susan M. Freier, Huynh-Hoa Bui, Paymaan Jafar-nejad, Frank Rigo
Filed: 14 Jan 22
Utility
Selective Reduction of Allelic Variants
22 Dec 22
Disclosed herein are antisense compounds and methods for selectively reducing expression of an allelic variant of a gene containing a single nucleotide polymorphism (SNP).
C. Frank Bennett, Susan M. Freier, Sarah Greenlee, Eric E. Swayze
Filed: 18 Jan 22
Utility
Modulation of Angiopoietin-Like 3 Expression
22 Dec 22
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Susan M. FREIER, Mark J. GRAHAM, Rosanne M. CROOKE
Filed: 11 Aug 21
Utility
Compounds and Methods for Reducing App Expression
1 Dec 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of APP RNA in a cell or animal, and in certain instances reducing the amount of APP protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease.
Susan M. Freier, Huynh-Hoa Bui, Holly Kordasiewicz, Eric E. Swayze
Filed: 29 Jan 20
Utility
Antisense Compounds and Uses Thereof
24 Nov 22
The present invention provides compounds comprising oligonucleotides complementary to a pyruvate kinase M transcript.
Frank Rigo, C. Frank Bennett, Adrian R. Krainer, Zhenxun Wang
Filed: 16 Dec 21
Utility
Compositions and Methods for Modulating Angiopoietin-like 3 Expression
13 Oct 22
Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal.
Thazha P. PRAKASH, Punit P. SETH, Eric E. SWAYZE, Susan M. FREIER, Mark J. GRAHAM, Rosanne M. CROOKE
Filed: 1 Dec 20
Utility
Compounds and Methods for Reducing Snca Expression
6 Oct 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SNCA mRNA in a cell or animal, and in certain instances reducing the amount of alpha-synuclein protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease.
Holly Kordasiewicz, Priyam Singh, Susan M. Freier, Tracy A. Cole
Filed: 9 Nov 21
Utility
Modulators of YAP1 Expression
6 Oct 22
The present embodiments provide methods, compounds, and compositions useful for inhibiting YAP1 expression, which may be useful for treating, preventing, or ameliorating a cancer associated with YAP1.
Youngsoo Kim, Xiaolin Luo, Robert MacLeod, Susan M. Freier, Huynh-Hoa Bui
Filed: 16 Nov 21
Utility
Compounds and Methods for Modulating Angiotensinogen Expression
22 Sep 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of AGT RNA in a cell or subject, and in certain instances reducing the amount of AGT in a cell or subject.
Adam Mullick, Susan M. Freier
Filed: 2 Jun 22
Utility
2'-METHOXY Substituted Oligomeric Compounds and Compositions for Use In Gene Modulations
15 Sep 22
Compositions comprising first and second oligomers are provided wherein at least a portion of the first oligomer is capable of hybridizing with at least a portion of the second oligomer, at least a portion of the first oligomer is complementary to and capable of hybridizing to a selected target nucleic acid, and at least one of the first or second oligomers includes a modified sugar and/or backbone modification.
Stanley T. Crooke
Filed: 3 Nov 21
Utility
Compounds and Methods for Reducing Spdef Expression
15 Sep 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of SPDEF RNA in a cell or subject, and in certain instances reducing the amount of SPDEF protein in a cell or subject.
Susan M. Freier, Huynh-Hoa Bui, Shuling Guo, Jeffrey R. Crosby
Filed: 22 Oct 21
Utility
Compounds and Methods for Modulating ATXN1
15 Sep 22
Provided are compounds, methods, and pharmaceutical compositions for reducing the amount or activity of ATXN1 RNA in a cell or subject, and in certain instances reducing the amount of ATXN1 in a cell or subject.
Keming Zhou
Filed: 23 May 22
Utility
Trans-cyclooctene Labeled Antisense Oligonucleotides, Radio Labeled Tetrazine and Methods
15 Sep 22
Featured are trans-cyclooctene and tetrazine compounds.
Brendon Ellery COOK, Maciej Adam KALISZCZAK, Laurent MARTARELLO, Nathan Edward GENUNG, Sivaraman DANDAPANI, Eric Edward SWAYZE, William John DRURY, III, Chrissa Ann DWYER
Filed: 19 Aug 20
Utility
Compounds and Methods for Modulating CLN3 Expression
8 Sep 22
Provided are compounds, methods, and pharmaceutical compositions for modulating the expression of CLN3 RNA in a cell or animal, and in certain instances modulating the expression of CLN3 protein in a cell or animal Such compounds, methods, and pharmaceutical compositions are useful to ameliorate at least one symptom or hallmark of a neurodegenerative disease.
Michelle L. Hastings, Frank Rigo
Filed: 10 Sep 19
Utility
Modulators of HSD17B13 Expression
1 Sep 22
Methods, compounds, and compositions useful for inhibiting HSD expression are provided.
Susan M. Freier, Susan F. MURRAY
Filed: 20 Dec 19
Utility
CorrectedCompositions and Methods for Modulating TTR Expression
1 Sep 22
Provided herein are oligomeric compounds with conjugate groups.
Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
Filed: 13 Feb 20
Utility
Compounds and Methods for Modulating TMPRSS6 Expression
18 Aug 22
Disclosed herein are compositions and compounds comprising modified oligonucleotides for modulating TMPRSS6 and modulating an iron accumulation disease, disorder and/or condition in an individual in need thereof.
Shuling Guo, Mariam Aghajan, Eric E. Swayze
Filed: 24 Sep 21